If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
372
results.
Updated on
24/10/2026 [08:50:00]
Results 175 to 200 of 372
Absstract of: CN122768451A
0001 本发明属于神经退行性疾病治疗技术领域，具体涉及通过调控神经元Sortilin‑1（SORT1）蛋白的表达或功能活性，预防、治疗阿尔茨海默病（Alzheimer's Disease,·AD）的方法与药物组合物；同时涉及调控神经元‑小胶质细胞信号通路，维持神经元内体稳态、抑制小胶质细胞异常促炎活化、减轻神经炎症、保护神经元功能的技术方案。
Absstract of: CN122772104A
本发明提供了一种抗eMTBR‑tau243蛋白片段的单克隆抗体及其应用和产品，涉及生物技术领域。本发明提供的抗eMTBR‑tau243蛋白片段的单克隆抗体，能够特异性结合tau蛋白片段（aa225‑242），以及包含这个片段的tau蛋白片段（aa1‑256）以及全长tau蛋白（2N4R，aa1‑441），能够用于上述蛋白检测产品的制备。
Absstract of: KR20260138113A
본 발명은 단백질의 초기 응집 거동을 관찰할 수 있는 단백질의 응집 거동 관찰 장치 및 이를 이용한 단백질의 응집 거동 관찰 방법에 관한 것이다.
Absstract of: CN122772105A
发明公开了一种抗人Aβ40的抗体及其应用。所述抗体含重链可变区VH和轻链可变区VL；所述VH包含HCDR1、HCDR2和HCDR3，所述VL包含LCDR1、LCDR2和LCDR3；所述HCDR1‑HCDR3分别包含如SEQ ID NO:1‑3所示的氨基酸序列，所述LCDR1‑LCDR3分别包含如SEQ ID NO:4‑6所示的氨基酸序列。本发明的抗体灵敏性高、特异性好，基于该抗体对人Aβ40进行免疫检测，操作简单、灵敏度高、特异性强，可实现人Aβ40的快速检测，对评估人Aβ40具有重要意义。
Absstract of: CN122775828A
0001 本发明公开一种用于加工黄精的综合质量评价方法及在制备抗衰老产品中的应用。本发明的方法通过主客观权重协同优化与数据标准化处理构建科学评价模型，采用合适的综合评分法实现了对加工黄精的综合质量评价，进而指导工艺参数优化，同时提升主要活性成分保留率与稳定性，实现质量与效率的双重提升。本发明还进行了加工黄精的提取物在改善衰老动物记忆下降中的功效研究，通过构建的具有阿尔茨海默病特征的动物模型的功效相关研究结果表明，包含黄精粗多糖或黄精粗皂苷的黄精加工产品能够有效改善运动障碍、认知功能障碍和脑区Aβ病理性斑块的蓄积，同时具有显著的脑部细胞凋亡抑制作用。
Absstract of: WO2025144847A1
The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.
Absstract of: US20260272867A1
The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Absstract of: US20260276656A1
The present invention concerns new approaches for the diagnosis and treatment of dementia diseases. In particular, the present invention pertains to new markers for diagnosing dementia diseases as well as to new targets for the treatment of dementia diseases.
Absstract of: US20260276657A1
Disclosed herein are antibodies, antibody fragments, binding agents, and compositions that specifically recognize protein variant biomarkers associated with frontotemporal dementia, kits and methods of use, including diagnosing, monitoring and treating frontotemporal dementia.
Absstract of: AU2026205448A1
Abstract Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a uPAR-specific chimeric antigen receptor. Also disclosed herein are methods for using the engineered immune cells of the present technology to treat or ameliorate the effects of cancer and senescence-associated pathologies (e.g., lung fibrosis, atherosclerosis, Alzheimer's disease, diabetes, liver fibrosis, chronic kidney disease, aging, or osteoarthritis) by selectively targeting senescent cells. Also provided herein are methods for detecting the senescent cell burden in a patient. Abstract
Absstract of: WO2026193298A1
Described herein is a method of diagnosing or predicting the risk of cognitive decline in a subject, and/or stratifying the subject according to the risk. The method comprises determining a profile of the subject; and predicting the risk based on the profile, or stratifying the subject to a high risk group or a low risk group based on the predicted risk. The profile comprises blood pressure; and the level of homocysteine (Hyc) in a biological sample from the subject. Also described herein is a method of treating, ameliorating, and/or preventing cognitive decline in the subject based on the prediction of the risk.
Absstract of: WO2026190495A1
The present invention refers to the field of in-vitro neural network stimulation, and particularly to devices that utilize cell cultures on multi-electrode arrays (MEAs) for investigating neuronal activity in research and drug testing applications. The invention consists of a closed loop system wherein a computational model stimulates via the electrodes of a MEA, cultured neurons on top of the MEA in order to produce disease- like activity states. The produced activity feeds back to the computational model, in real or periodic time, producing a hybrid neuronal population that can be used for drug screening. The respective method for the application of the abovementioned system is also disclosed.
Absstract of: WO2026190230A1
The present invention relates to alpha-synuclein antibodies which are useful in diagnostic assays for detecting aggregates, oligomers and fibrillar forms of alpha- synuclein in patient samples. These antibodies enable diagnosis and efficient treatment of alpha-synucleinopathies such as Parkinson's Disease (PD) or Multiple System Atrophy (MSA) patients by assessing and monitoring the pathological alpha-synuclein levels in patients.
Absstract of: WO2026193412A1
Among other things, the present disclosure provides adenoviral vectors, genomes, and methods of use thereof. In some embodiments, the present disclosure provides methods of in vivo gene therapy comprising administration of an adenoviral payload vector and an adenoviral integration vector. The present disclosure provides, among other things, compositions comprising an adenoviral payload vector and an adenoviral integration vector for use in, e.g., methods of in vivo gene therapy. In some embodiments, the present disclosure provides adenoviral vectors, genomes, and compositions thereof comprising a therapeutic sequence, e.g., a nucleic acid sequence encoding a CYBB therapeutic polypeptide. In some embodiments, the present disclosure provides methods of treating various conditions, disorders, and diseases, e.g., chronic granulomatous disease.
Absstract of: WO2026193026A1
The invention provides methods for determining if a subject suffering from SARS-CoV-2 infection is susceptible to developing fibromyalgia. Also provided herein are methods for identifying if a subject possesses a disease or condition characterized or caused by an immune system deficiency, such as chronic pain or fatigue, long COVID or interstitial cystitis (IC).
Absstract of: US20260273141A1
Disclosed herein are methods of inhibiting sterile alpha and TIR motif-containing protein 1 (SARM1) NADase activity in an axon. The methods can also be used to reduce or delay degeneration in an axon, treat or prevent degeneration of an injured axon, enhance fusion of one or more severed axons, and delay degeneration of one or more fused axons, as well as treat a neurological nerve injury or a neurodegenerative disease in a subject in need thereof using a SARM 1 inhibitor.
Absstract of: WO2026189109A1
A high-sensitivity immunoassay method and system. The high-sensitivity immunoassay method for a target protein comprises: capturing the target protein to obtain a solution containing an immune complex; spreading said solution on a detection substrate under the action of a passive driving mechanism; immobilizing the immune complex on at least one surface; and performing detection and calculating the concentration of the immune complex. The immunoassay method uses a consumable structure having a simple structure and low costs, achieving highly sensitive detection of a target protein to be tested.
Absstract of: US20260276651A1
0000 The present invention relates to methods for identifying the splicing of RAGE pre-mRNA resulting in the inclusion of exon 9b and/or exclusion of exon 10 in a subject in a subject who has received, or is receiving an antisense oligonucleotide that modulates RAGE pre-mRNA splicing. In one aspect, the present invention provides a method for determining endogenous soluble receptor for advanced glycation end products (RAGE) level in the lung of a subject, the method comprising: determining the presence of endogenous soluble RAGE in a blood sample from a subject who has received or is receiving a treatment administered to their respiratory tract, wherein the treatment increases endogenous soluble RAGE, wherein the level of endogenous soluble RAGE in the blood sample correlates with the endogenous soluble RAGE level in the lung of the subject.
Absstract of: US20260276659A1
A method includes estimating a value of a parameter indicative of an age or lifespan of a population of red blood cells of a subject, estimating a value of average glucose (AG) of the subject based on (i) the value of the parameter and (ii) a value indicative of an amount of glycated hemoglobin (HbA1c) of the subject, and providing information for treatment or diagnosis of a hyperglycemia condition of the subject based on the estimated value of AG.
Absstract of: AU2025235500A1
Methods for improving brain function and increasing brain activity by oral administration of choline are provided. Compositions including unit doses of choline sufficient to provide improved brain function and increasing brain activity are also provided. In some embodiments, it includes a method for improving brain function and/or increasing brain efficiency in a subject in need thereof, the methods comprising administering a pharmaceutical composition comprising 550 mg or greater of choline. The increases in brain efficiency are measured by functional Magnetic Resonance Imaging, as compared to placebo, when the subject is performing an N-Back task.
Absstract of: WO2025054130A1
The present disclosure relates to enzymes capable of oxidizing betahydroxybutyrate (BHB). In aspects, the enzymes are engineered to optimize BHB activity. Engineered enzymes including amino acid substitutions, truncations, and sequence deletions are further provided. The disclosure further provides for use of enzymes described herein, for example, in test strips, BHB sensors, devices, and systems for detecting and measuring BHB concentration.
Absstract of: AU2025232230A1
Disclosed herein are chemical probes for unfolded, misfolded or intrinsically disordered proteins, in particular chemical probes having the structure of Formula I or salts thereof, and to the use of the probes for various applications relating to unfolded, misfolded or intrinsically disordered proteins, for example, for diagnosing or prognosing a disease or disorder associated with an unfolded, misfolded or intrinsically disordered protein.
Absstract of: US20260272976A1
0000 Described herein are methods of monitoring and treating a subject with ALS based on biomarkers.
Absstract of: WO2026191421A1
Provided are a dementia diagnosis system and a dementia diagnosis program that are capable of identifying a patient having dementia with high accuracy by a simple and easy test. A dementia diagnosis system (1) has: a measurement unit (51) that continuously measures the acidity/basicity of a body fluid obtained from a subject; a confirmation unit (52) that confirms, for the acidity/basicity continuously measured by the measurement unit (51), an outlier at which the acidity/basicity becomes alkaline and the presence or absence of a change point at which the acidity/basicity persistently shifts to the alkaline side after the outlier is confirmed; and a prediction unit (53) that predicts whether or not the subject has dementia on the basis of the confirmation result of the confirmation unit (52).
Nº publicación: WO2026193055A1 17/09/2026
Applicant:
MASSACHUSETTS EYE AND EAR INFIRMARY [US]
THE GENERAL HOSPITAL CORP [US]
MASSACHUSETTS EYE AND EAR INFIRMARY
THE GENERAL HOSPITAL CORPORATION
Absstract of: WO2026193055A1
Described herein are humanized anti-ApoE antibody molecules, antigen-binding portions thereof, and uses thereof.
BOPI
Electronic site
